Plus Therapeutics Inc (PSTV) concluded trading on Thursday at a closing price of $0.35, with 2.99 million shares of worth about $1.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -74.13% during that period and on June 12, 2025 the price saw a gain of about 5.82%. Currently the company’s common shares owned by public are about 32.72M shares, out of which, 29.81M shares are available for trading.
Stock saw a price change of 9.47% in past 5 days and over the past one month there was a price change of -49.97%. Year-to-date (YTD), PSTV shares are showing a performance of -69.63% which decreased to -84.20% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $2.33 during that period. The average intraday trading volume for Plus Therapeutics Inc shares is 12.82 million. The stock is currently trading 2.87% above its 20-day simple moving average (SMA20), while that difference is down -38.47% for SMA50 and it goes to -67.61% lower than SMA200.
Plus Therapeutics Inc (NASDAQ: PSTV) currently have 32.72M outstanding shares and institutions hold larger chunk of about 4.89% of that.
The stock has a current market capitalization of $11.43M and its 3Y-monthly beta is at 0.63. It has posted earnings per share of -$2.50 in the same period. It has Quick Ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PSTV, volatility over the week remained 5.77% while standing at 10.05% over the month.
Analysts are in expectations that Plus Therapeutics Inc (PSTV) stock would likely to be making an EPS of -0.23 in the current quarter, while forecast for next quarter EPS is -0.23 and it is -0.76 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.45 which is -0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.45 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 62.82% while it is estimated to increase by 7.93% in next year. EPS is likely to grow at an annualized rate of 49.89% for next 5-years, compared to annual growth of 46.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by D. Boral Capital on March 17, 2025 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by Ladenburg Thalmann stated Plus Therapeutics Inc (PSTV) stock as a Buy in their note to investors on January 25, 2021, suggesting a price target of $8 for the stock.
